Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development.

OBJECTIVE To investigate the role of matrix metalloproteinase 13 (MMP-13; collagenase 3) in osteoarthritis (OA). METHODS OA was surgically induced in the knees of MMP-13-knockout mice and wild-type mice, and mice were compared. Histologic scoring of femoral and tibial cartilage aggrecan loss (0-3 scale), erosion (0-7 scale), and chondrocyte hypertrophy (0-1 scale), as well as osteophyte size (0-3 scale) and maturity (0-3 scale) was performed. Serial sections were stained for type X collagen and the MMP-generated aggrecan neoepitope DIPEN. RESULTS Following surgery, aggrecan loss and cartilage erosion were more severe in the tibia than femur (P<0.01) and tibial cartilage erosion increased with time (P<0.05) in wild-type mice. Cartilaginous osteophytes were present at 4 weeks and underwent ossification, with size and maturity increasing by 8 weeks (P<0.01). There was no difference between genotypes in aggrecan loss or cartilage erosion at 4 weeks. There was less tibial cartilage erosion in knockout mice than in wild-type mice at 8 weeks (P<0.02). Cartilaginous osteophytes were larger in knockout mice at 4 weeks (P<0.01), but by 8 weeks osteophyte maturity and size were no different from those in wild-type mice. Articular chondrocyte hypertrophy with positive type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints. CONCLUSION Our findings indicate that structural cartilage damage in a mouse model of OA is dependent on MMP-13 activity. Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion. MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.

[1]  T. Ochi,et al.  Early closure of growth plate causes poor growth of long bones in collagen-induced arthritis rats. , 2002, Journal of musculoskeletal & neuronal interactions.

[2]  K. Brew,et al.  The Roles of Substrate Thermal Stability and P2 and P1′ Subsite Identity on Matrix Metalloproteinase Triple-helical Peptidase Activity and Collagen Specificity* , 2006, Journal of Biological Chemistry.

[3]  T. Spector,et al.  Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study , 2007, Arthritis research & therapy.

[4]  C. Little,et al.  Spatial and Temporal Localization of Transforming Growth Factor-&bgr;, Fibroblast Growth Factor-2, and Osteonectin, and Identification of Cells Expressing &agr;-Smooth Muscle Actin in the Injured Anulus Fibrosus: Implications for Extracellular Matrix Repair , 2002, Spine.

[5]  P. Anract,et al.  Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. , 2005, Arthritis and rheumatism.

[6]  V. Quesada,et al.  Identification and Enzymatic Characterization of Two Diverging Murine Counterparts of Human Interstitial Collagenase (MMP-1) Expressed at Sites of Embryo Implantation* , 2001, The Journal of Biological Chemistry.

[7]  Christopher M. Overall,et al.  In search of partners: linking extracellular proteases to substrates , 2007, Nature Reviews Molecular Cell Biology.

[8]  H. V. Van Wart,et al.  Proteolysis Involving Matrix Metalloproteinase 13 (Collagenase‐3) Is Required for Chondrocyte Differentiation That Is Associated with Matrix Mineralization , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  R. Copeland,et al.  Aggrecan Protects Cartilage Collagen from Proteolytic Cleavage* , 2003, Journal of Biological Chemistry.

[10]  C. Little,et al.  Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. , 2007, The Journal of clinical investigation.

[11]  Claus Christiansen,et al.  Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.

[12]  K. Cheah,et al.  Expression of collagen and aggrecan genes in normal and osteoarthritic murine knee joints. , 2002, Osteoarthritis and cartilage.

[13]  C. López-Otín,et al.  Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). , 1997, European journal of biochemistry.

[14]  W. Horton,et al.  Age-related expression patterns of Bag-1 and Bcl-2 in growth plate and articular chondrocytes. , 2004, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[15]  Kozo Nakamura,et al.  Osteoarthritis development in novel experimental mouse models induced by knee joint instability. , 2005, Osteoarthritis and cartilage.

[16]  H. Kawaguchi.  Regulation of Osteoarthritis Development by Wnt–β‐catenin Signaling Through the Endochondral Ossification Process , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  S. Kokubun,et al.  Apoptosis And Proliferation Of Growth Plate Chondrocytes In Rabbits , 1997 .

[18]  C. Little,et al.  Modulating chondrocyte hypertrophy in growth plate and osteoarthritic cartilage. , 2008, Journal of musculoskeletal & neuronal interactions.

[19]  J. Pelletier,et al.  Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site , 2006, Arthritis research & therapy.

[20]  Y. Liu,et al.  Yeast Nuclear Extract Contains Two Major Forms of RNA Polymerase II Mediator Complexes* , 2001, Journal of Biological Chemistry.

[21]  S. Glasson,et al.  The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. , 2007, Osteoarthritis and cartilage.

[22]  M. Kashiwagi,et al.  Aggrecanases and cartilage matrix degradation , 2003, Arthritis research & therapy.

[23]  H. Ma,et al.  Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis , 2005, Nature.

[24]  Z. Werb,et al.  Altered endochondral bone development in matrix metalloproteinase 13-deficient mice , 2004, Development.

[25]  C. Rorabeck,et al.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.

[26]  A. Poole,et al.  Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. , 2001, The Journal of clinical investigation.

[27]  D. Zukor,et al.  Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). , 2000, Arthritis and rheumatism.

[28]  A. Poole,et al.  Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis. , 2009, Osteoarthritis and cartilage.

[29]  Anne M Manicone,et al.  Matrix metalloproteinases as modulators of inflammation. , 2008, Seminars in cell & developmental biology.

[30]  T. Aigner,et al.  Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. , 2002, Arthritis and rheumatism.

[31]  C. López-Otín,et al.  The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction* , 1997, The Journal of Biological Chemistry.

[32]  Y. Okada,et al.  Joint diseases and matrix metalloproteinases: a role for MMP-13. , 2008, Current pharmaceutical biotechnology.

[33]  Z. Werb,et al.  Role of Matrix Metalloproteinase 13 in Both Endochondral and Intramembranous Ossification during Skeletal Regeneration , 2007, PloS one.

[34]  A. Parker,et al.  Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.

[35]  A Zien,et al.  Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. , 2001, Arthritis and rheumatism.

[36]  R. Maciewicz,et al.  Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage Patterns , 2000, The Journal of Biological Chemistry.

[37]  Kozo Nakamura,et al.  Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. , 2006, Arthritis and rheumatism.

[38]  K Henriksen,et al.  Should subchondral bone turnover be targeted when treating osteoarthritis? , 2008, Osteoarthritis and cartilage.

[39]  C. Little,et al.  Mechanisms involved in cartilage proteoglycan catabolism. , 2000, Matrix biology : journal of the International Society for Matrix Biology.

[40]  A. Poole,et al.  Increased type II collagen degradation and very early focal cartilage degeneration is associated with upregulation of chondrocyte differentiation related genes in early human articular cartilage lesions. , 2005, The Journal of rheumatology.

[41]  C. López-Otín,et al.  Collagenase 3 Is a Target of Cbfa1, a Transcription Factor of the runt Gene Family Involved in Bone Formation , 1999, Molecular and Cellular Biology.

[42]  Tomoyuki Sasaki,et al.  MRI evaluation of growth plate closure rate and pattern in the normal knee joint. , 2002, The journal of knee surgery.

[43]  A. Bendele,et al.  Induction of osteoarthritis in the rat by surgical tear of the meniscus: Inhibition of joint damage by a matrix metalloproteinase inhibitor. , 2002, Osteoarthritis and cartilage.

[44]  D. Zukor,et al.  Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. , 2002, Arthritis & Rheumatism.

[45]  Mahboob Rahman,et al.  Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Kozo Nakamura,et al.  Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. , 2007, Biochemical and biophysical research communications.

[47]  S. Donell,et al.  Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage , 2006, Arthritis research & therapy.

[48]  A. Fosang,et al.  ADAMTS-5: the story so far. , 2008, European cells & materials.

[49]  R. D. Dyer,et al.  Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects* , 2007, Journal of Biological Chemistry.

[50]  M. Tiku,et al.  Matrix metalloproteinase-13 influences ERK signalling in articular rabbit chondrocytes. , 2006, Osteoarthritis and cartilage.

[51]  A. Fourie,et al.  ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro , 2005, Nature.

[52]  E. Tchetina,et al.  Chondrocyte hypertrophy can be induced by a cryptic sequence of type II collagen and is accompanied by the induction of MMP-13 and collagenase activity: implications for development and arthritis. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[53]  R. Mason,et al.  Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis. , 2002, Osteoarthritis and cartilage.